Home › Acute Myeloid Leukemia › New Jersey
Acute Myeloid Leukemia clinical trials in New Jersey
32 studies for Acute Myeloid Leukemia are looking for participants at sites in New Jersey.
Cities in New Jersey
- Edison20 studies
- Clifton12 studies
- Newark12 studies
- Paterson7 studies
- Brick7 studies
- Toms River5 studies
- Camden4 studies
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Englewood Hospital and Medical Center, Englewood
- Hackettstown Medical Center, Hackettstown
- Morristown Medical Center, Morristown
- and 6 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Monmouth, Middletown
- Memorial Sloan Kettering Bergen, Montvale
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06484062A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
RecruitingPhase 1
Ages 12 to 78 · All sexes · Updated Sep 29, 2026 · NCT03802695Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Cooperman Barnabas Medical Center, Livingston
- Monmouth Medical Center, Long Branch
- and 6 more
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Sep 28, 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Cooper Hospital University Medical Center, Camden
- Cooperman Barnabas Medical Center, Livingston
- and 7 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Cooperman Barnabas Medical Center, Livingston
- Monmouth Medical Center, Long Branch
- and 6 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06317649A Study of CRD3874-SI in People With Leukemia
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (All protocol activities), Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07661095Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Cooperman Barnabas Medical Center, Livingston
- Monmouth Medical Center, Long Branch
- and 4 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Cooper Hospital University Medical Center, Camden
- Cooperman Barnabas Medical Center, Livingston
- and 7 more
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Sep 22, 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Hackensack University Medical Center, Hackensack
- Morristown Medical Center, Morristown
- Jersey Shore Medical Center, Neptune City
- and 4 more
RecruitingPhase 3
6 Months – 21 Years · All sexes · Updated Sep 17, 2026 · NCT04293562Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- John Theurer Cancer Center at Hackensack UMC, Hackensack
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06824168Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Atlantic Health, Morristown
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Hackensack University Medical Center, Hackensack
- Morristown Medical Center, Morristown
- Jersey Shore Medical Center, Neptune City
- and 3 more
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Hackensack University Medical Center, HMH, Hackensack
- Morristown Medical Center, Morristown
RecruitingPhase 3
29 Days – 21 Years · All sexes · Updated Aug 24, 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Rutgers Biomedical and Health Sciences, New Brunswick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)
- MDA at Cooper University Health Care, Camden
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07771803L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- Atlantic Health, Morristown
RecruitingPhase 2/3
Ages 18 to 80 · All sexes · Updated Aug 5, 2026 · NCT06788756A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
- Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Jul 17, 2026 · NCT07392242Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Hackensack University Medical Center, Hackensack
- Robert Wood Johnson/Cancer Institute of New Jersey, New Brunswick
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Monmouth, Middletown
- Memorial Sloan Kettering Bergen, Montvale
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT05756777A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RecruitingPhase 1
Ages 1 and older · All sexes · Updated Jun 22, 2026 · NCT06017258A Study of Revumenib and Mezigdomide in People With Leukemia
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Jun 22, 2026 · NCT07356154A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Jun 17, 2026 · NCT07011004A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- John Theurer Cancer Center / Hackensack University, Hackensack
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Atlantic Health, Morristown
- Rutgers Cancer Institute of New Jersey, New Brunswick
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Mar 24, 2026 · NCT04988555Phase IB/II of CPX-351 for Relapse Prevention in AML
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 23, 2026 · NCT04990102A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Hackensack University Medical Center, Hackensack
- Rutgers Cancer Institute, New Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 10, 2026 · NCT05748197A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 24, 2026 · NCT06773208From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.